Tuesday, 17 November 2026European Markets

ERYTECH PHARMA Stock Bearish By 15% In The Last 5 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of erytech pharma (cac 40: eryp.pa) fell by a staggering 15.75% in 5 sessions from €0.91 to €0.77 at 01:56 est on monday, after four sequential sessions in a row of losses. cac 40 is falling 1.78% to €7,187.27, following the last session's downward trend.

erytech pharma's last close was €0.77, 65.86% under its 52-week high of €2.26.

about erytech pharma

erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.

earnings per share

as for profitability, erytech pharma has a trailing twelve months eps of €-0.93.

volatility

erytech pharma's last week, last month's, and last quarter's current intraday variation average was a negative 1.95%, a positive 2.10%, and a positive 5.68%.

erytech pharma's highest amplitude of average volatility was 3.30% (last week), 7.31% (last month), and 5.68% (last quarter).

earnings before interest, taxes, depreciation, and amortization

erytech pharma's ebitda is 7.45.

revenue growth

year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2m for the twelve trailing months.

more news about erytech pharma (eryp.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 27 Feb 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›